REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 10

AstraZenecaAnnouncement

07/03/2017 14:30

- Part 10: For the preceding part double click  ID:nRSG7691Yi 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   against the Company or individual directors. Serious fraud may lead to potential prosecution or even imprisonment of senior management.                                                                                                                         
 
 
APPENDIX B 
 
This statement relates to and is extracted from the Annual Report. It is
repeated here solely for the purpose of complying with DTR 6.3.5. It is not
connected to the information presented in this announcement or in the
Company's fourth quarter and full year results 2016 announcement that was
published on 2 February 2017. 
 
Directors' responsibility statement pursuant to DTR 4 
 
The Directors confirm that to the best of our knowledge: 
 
·      The Financial Statements, prepared in accordance with the applicable
set of accounting standards, give a true and fair view of the assets,
liabilities, financial position and profit or loss of the Company and the
undertakings included in the consolidation taken as a whole. 
 
·      The Directors' Report includes a fair review of the development and
performance of the business and the position of the issuer and the
undertakings included in the consolidation taken as a whole, together with a
description of the principal risks and uncertainties that they face. 
 
On behalf of the Board of Directors on 2 February 2017 
 
Pascal Soriot 
 
Director 
 
APPENDIX C 
 
Related party transactions 
 
The Group had no material related party transactions which might reasonably be
expected to influence decisions made by the users of these Financial
Statements. 
 
About AstraZeneca 
 
AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three main therapy areas -
Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company
also is selectively active in the areas of Autoimmunity, Neuroscience and
Infection. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. 
 
 Media Enquiries                                                                
 Esra Erkal-Paler     UK/Global                               +44 203 749 5638  
 Vanessa Rhodes       UK/Global                               +44 203 749 5736  
 Karen Birmingham     UK/Global                               +44 203 749 5634  
 Rob Skelding         UK/Global                               +44 203 749 5821  
 Jacob Lund           Sweden                                  +46 8 553 260 20  
 Michele Meixell      US                                      +1 302 885 2677   
 Investor Relations                                                             
 Thomas Kudsk Larsen                                          +44 203 749 5712  
 Craig Marks          Finance, Fixed Income, M&A              +44 7881 615 764  
 Henry Wheeler        Oncology                                +44 203 749 5797  
 Mitchell Chan        Oncology                                +1 240 477 3771   
 Lindsey Trickett     Cardiovascular & Metabolic Diseases     +1 240 543 7970   
 Nick Stone           Respiratory                             +44 203 749 5716  
 Christer Gruvris     Autoimmunity, Neuroscience & Infection  +44 203 749 5711  
 US toll free                                                 +1 866 381 7277   
 
 
This information is provided by RNS
The company news service from the London Stock Exchange